Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer.

MedStar author(s):
Citation: Journal of Nuclear Medicine. 61(3):397-404, 2020 03.PMID: 31451488Institution: MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment: Medicine/Endocrinology | Medicine/Nuclear MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Government Agencies/lj [Legislation & Jurisprudence] | *Iodine Radioisotopes/tu [Therapeutic Use] | *Patient Discharge/lj [Legislation & Jurisprudence] | *Policy | *Surveys and Questionnaires | *Thyroid Neoplasms/rt [Radiotherapy] | Humans | Outpatients/lj [Legislation & Jurisprudence]Year: 2020Local holdings: Available online from MWHC library: 1964 - present, Available in print through MWHC library: 1999 - 2006ISSN:
  • 0161-5505
Name of journal: Journal of nuclear medicine : official publication, Society of Nuclear MedicineAbstract: The objective of this nationwide survey was to evaluate whether there has been a change in the practice regarding hospital release of differentiated thyroid cancer patients treated with 131I since the publication of Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 addressing patient release. Methods: A survey was emailed to ~25,000 members of ThyCa: Thyroid Cancer Survivors' Association, Inc. and was available online from March-August 2018. Responses were included from adult patients regarding their most recent 131I therapy received between 2011-2018 (post2011). Responses to this survey were compared to those of a similar previous survey for 131I therapies received between 1997-2009 (pre2009). Results: Of the 2,136 responses, 1,111 met the inclusion criteria. A similar percentage (~98%) of patients were given oral and/or written radiation safety instructions (RSI) post2011 and pre2009 with a shift away from nuclear medicine physicians providing instructions post2011 (43%) than pre2009 (54%; p<0.001). More patients were able to discuss and individualize the RSI post2011 (67%) than pre2009 (29%; p<0.001). However, 2% of patients do not recall ever receiving RSI post2011. Since 2011, more patients were treated as outpatients (87%) than before 2009 (66%; P<0.001). For outpatients, more patients were discharged within 30 minutes after receiving 131I therapy post2011 (78%) than pre2009 (72%; P = 0.002). The same percentage (0.6%) of patients travelled >2 hours with >=2 occupants in the vehicle within approximately one meter of the patient post2011 and pre2009. Immediately post-therapy, a similar percentage of patients stayed in a non-private residence post2011 (4%) and pre2009 (5%; P = 0.28). Of the 27 outpatients released within 30 minutes to non-private residences, two patients received 5.55-11.1 GBq (150-299 mCi) of 131I. Conclusion: This survey suggests that since publication of the Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 regarding patient release after radioiodine therapy, there has been improvements in some radiation safety practices on release of outpatients, and in patient compliance on travel and lodging. Copyright (c) 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.All authors: Bloom G, Burman KD, Gomes-Lima CJ, Van Nostrand D, Wartofsky L, Wu DOriginally published: Journal of Nuclear Medicine. 2019 Aug 26Fiscal year: FY2020Digital Object Identifier: Date added to catalog: 2019-10-10
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 31451488 Available 31451488

Available online from MWHC library: 1964 - present, Available in print through MWHC library: 1999 - 2006

The objective of this nationwide survey was to evaluate whether there has been a change in the practice regarding hospital release of differentiated thyroid cancer patients treated with 131I since the publication of Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 addressing patient release. Methods: A survey was emailed to ~25,000 members of ThyCa: Thyroid Cancer Survivors' Association, Inc. and was available online from March-August 2018. Responses were included from adult patients regarding their most recent 131I therapy received between 2011-2018 (post2011). Responses to this survey were compared to those of a similar previous survey for 131I therapies received between 1997-2009 (pre2009). Results: Of the 2,136 responses, 1,111 met the inclusion criteria. A similar percentage (~98%) of patients were given oral and/or written radiation safety instructions (RSI) post2011 and pre2009 with a shift away from nuclear medicine physicians providing instructions post2011 (43%) than pre2009 (54%; p<0.001). More patients were able to discuss and individualize the RSI post2011 (67%) than pre2009 (29%; p<0.001). However, 2% of patients do not recall ever receiving RSI post2011. Since 2011, more patients were treated as outpatients (87%) than before 2009 (66%; P<0.001). For outpatients, more patients were discharged within 30 minutes after receiving 131I therapy post2011 (78%) than pre2009 (72%; P = 0.002). The same percentage (0.6%) of patients travelled >2 hours with >=2 occupants in the vehicle within approximately one meter of the patient post2011 and pre2009. Immediately post-therapy, a similar percentage of patients stayed in a non-private residence post2011 (4%) and pre2009 (5%; P = 0.28). Of the 27 outpatients released within 30 minutes to non-private residences, two patients received 5.55-11.1 GBq (150-299 mCi) of 131I. Conclusion: This survey suggests that since publication of the Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 regarding patient release after radioiodine therapy, there has been improvements in some radiation safety practices on release of outpatients, and in patient compliance on travel and lodging. Copyright (c) 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

English

Powered by Koha